NCT00464919: Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC) |
|
|
| Completed | 2 | 50 | RoW | Sorafenib, tegafur/uracil (UFUR®) | National Taiwan University Hospital | Hepatocellular Carcinoma | | 03/09 | | |
NCT00519688: UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma |
|
|
| Completed | 2 | 44 | RoW | Thalidomide, Thado, Tegafur/Uracil, UFUR | National Taiwan University Hospital | Hepatocellular Carcinoma | 08/10 | 08/10 | | |
NCT01539018: Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE |
|
|
| Terminated | 2 | 77 | RoW | Sorafenib, nexavar alone, sorafenib plus tegafur-uracil, nexavar plus UFT | Egyptian Society of Liver Cancer | Advanced Hepatocellular Carcinoma | 01/15 | 01/15 | | |
